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Purpose: To investigate the involvement of SPARC (secreted protein acidic and rich in cysteine) mutations and copy
number variation in juvenile-onset primary open-angle glaucoma (JPOAG).
Methods: This study involved the 27 family members from the GLC1M (glaucoma 1, open angle, M)-linked Philippine
pedigree with JPOAG, 46 unrelated Chinese patients with JPOAG and 95 controls. Mutation screening of the SPARC
sequence, covering the promoter, 5′-untranslated region (UTR), entire coding regions, exon-intron boundaries, and part
of the 3′-UTR, was performed using polymerase chain reaction and direct DNA sequencing. Copy number of the gene
was analyzed by three TaqMan copy number assays.
Results: No putative SPARC mutation was detected in the Philippine family. In the Chinese participants, 11 sequence
variants were detected. Two were novel: IVS2+8G>T and IVS2+32C>T. For the 9 known SNPs, one was synonymous
(rs2304052, p.Glu22Glu) and the others were located in noncoding regions. No individual SNP was associated with
JPOAG. Five of the most common SNPs, i.e., rs2116780, rs1978707, rs7719521, rs729853, and rs1053411, were contained
in a LD (linkage disequilibrium) block. Haplotype-based analysis showed that no haplotype was associated with the
disorder. Copy number analysis revealed that all study subjects had two copies of the gene, suggesting no correlation
between the copy number of SPARC and JPOAG.
Conclusions: We have excluded SPARC as the causal gene at the GLC1M locus in the Philippine pedigree and, for the
first time, revealed that the coding sequences, splice sites and copy number of SPARC do not contribute to JPOAG. Further
investigations are warranted to unravel the involvement of SPARC in the pathogenesis of other forms of glaucoma.
Glaucoma is a group of degenerative optic neuropathies
involving progressive loss of retinal ganglion cells and their
axons, resulting in a characteristic pattern of optic nerve head
and  visual  field  damage  [1,2].  It  is  the  leading  cause  of
irreversible  blindness  globally  [3].  Primary  open-angle
glaucoma (POAG), characterized by a gonioscopically open
anterior chamber angle, is a leading form of glaucoma in many
populations [4-6].
POAG has complex etiology. It could be monogenic, e.g.,
myocilin glaucoma, or multifactorial, resulting from additive
or interactive effects of environmental and genetic factors.
Intraocular pressure (IOP) is a major risk factor. Accordingly,
POAG  has  been  divided  into  high-tension  (HTG,
IOP>21 mmHg) and normal-tension (NTG, IOP≤21 mmHg)
entities, and it is considered a spectrum of disease reflecting
different  susceptibilities  to  a  given  IOP  level  [7].  The
trabecular meshwork (TM) provides the major resistance to
aqueous humor outflow in cases in which IOP is elevated
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[1,2].  Thus,  genetic  and/or  other  factors  affecting  IOP,
outflow facility, and retinal ganglion cell viability may play
important roles in POAG susceptibility.
To date, more than 20 linkage loci have been mapped for
POAG  [8-24].  However,  only  three  genes,  i.e.,  myocilin
(MYOC,GLC1A) [25], optineurin (OPTN,GLC1E) [26], and
WD  repeat  domain  36  (WDR36,GLC1G)  [18],  were
identified. These genes account for less than 10% of overall
POAG [27-30]. Causal genes in the rest of the loci and genes
independent  of  the  linkage  loci  remain  to  be  identified.
Candidate genes for POAG can be prioritized by at least six
criteria: (1) expressed in eye tissues; (2) involved in IOP
regulation; (3) affecting ganglion cell viability; (4) associated
with other eye or retinal diseases; (5) associated with other
neurodegenerative  diseases;  and  (6)  located  at  reported
linkage loci.
In  this  study,  we  evaluated  SPARC  (secreted  protein
acidic and rich in cysteine, OMIM 182120) as a candidate
gene for JPOAG. The SPARC gene is located at chromosomal
region  5q31.3-q32  within  the  GLC1M  locus  (5q22.1–32;
OMIM 610535) mapped by our group [20]. SPARC, also
known  as  osteonectin  or  BM-40,  is  a  matricellular
glycoprotein that functions primarily to promote extracellular
matrix deposition [31]. It is expressed at high levels in bone
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2016tissues and is distributed widely in many other tissues and cell
types [32]. In human eyes, SPARC is found in lens [33],
corneal epithelium [33], TM cells [34,35], and retinal pigment
epithelium [33,36,37]. It distributes throughout the trabecular
meshwork and is prominent in the juxtacanalicular region
[35]. In the trabecular meshwork of postmortem human eyes,
SPARC  and  another  glaucoma  gene  MYOC  responded
significantly to elevated-IOP [38]. SPARC is one of the most
highly upregulated genes in porcine TM cells in response to
mechanical stretching [39], supporting an important role of
SPARC  in  IOP  regulation  [35].  Furthermore,  elevated
expression of SPARC has been detected in the iris of POAG
patients [40], although whether such change was a cause or
consequence of glaucoma, or just a phenomenon secondary to
the  use  of  topical  medications  for  glaucoma  remained
unverified. Recently, the SPARC null mouse has been shown
to have lower IOP than the wild-type, likely due to decreased
outflow resistance. Moreover, heterozygous mice expressed
an intermediate phenotype suggestive of a dose-dependent
effect of SPARC [41]. These findings suggest that SPARC
could be implicated in POAG, likely by compromising the
regulation of IOP.
No study has yet evaluated the involvement of SPARC
mutations  in  human  glaucoma.  If  any  kind  of  SPARC
variations are associated with or causative for POAG, at least
5  possibilities  should  be  considered:  (1)  promoter
polymorphisms that affect the expression level of the gene;
(2)  missense  variants  with  gain  (or  loss)-of-function;  (3)
nonsense mutations leading to loss-of-function; (4) variants
at the exon-intron boundaries causing alternative splicing; and
(5) copy number variants that may alter gene dosage. In view
of the finding that SPARC null mice have lower IOPs [41], it
is  likely  additional  copies  of  SPARC  may  correlate  with
higher IOP. Moreover, as the GLC1M locus was identified in
a pedigree of juvenile-onset primary open-angle glaucoma
(JPOAG) with high IOP [20], we investigated the involvement
of SPARC variants in JPOAG by mutation screening and copy
number analysis.
METHODS
Participants:  The  protocol  was  approved  by  the  Ethics
Committee for Human Research, the Chinese University of
Hong  Kong.  All  procedures  adhered  to  the  tenets  of  the
Declaration  of  Helsinki.  Written  informed  consent  was
obtained from every participant after explanation of the nature
of the study.
The Philippine pedigree with JPOAG has been described
in  detail  previously  [20,42].  Briefly,  this  five-generation
family  comprised  95  members,  with  22  being  affected.
Peripheral venous blood was collected from 27 members, who
underwent complete ophthalmic examinations, and of whom
9 were affected. JPOAG was defined based on the following
criteria:  (1)  exclusion  of  secondary  causes,  e.g.,  trauma,
uveitis,  steroid-induced  or  exfoliation  glaucoma;  (2)
gonioscopically open anterior chamber angle, Shaffer grade
III or IV; (3) IOP≥22 mmHg in the affected eye measured by
applanation tonometry; (4) characteristic optic disc damage
and/or  typical  visual  field  loss  by  Humphrey  automated
perimetry using the Glaucoma Hemifield test; and (5) age at
diagnosis ≤40 years. For the affected subjects, the age at
diagnosis ranged from 12 to 33 years (mean±SD: 19±4.2
years),  the  highest  recorded  IOP  was  between  24  and
44 mmHg (32±6.3 mmHg), vertical cup-disc ratio (VCDR)
ranged from 0.7 to 0.9 (median: 0.8), and visual field loss was
compatible  with  glaucoma  in  two  consecutive  tests.  The
unaffected members aged from 3 to 73 years (25±19.9 years)
at study recruitment, with IOP <22 mmHg, VCDR between
0.2 and 0.5 (median: 0.3), and the visual field within normal
range.
Unrelated Chinese subjects were recruited from the eye
clinics of Hong Kong Eye Hospital. We enrolled 46 patients
with sporadic JPOAG and 95 controls (characteristics shown
in  Table  1).  They  were  given  complete  ophthalmic
examinations  and  were  diagnosed  using  the  same  criteria
described above. Of the patients, age at diagnosis ranged from
6 to 40 years conforming to JPOAG. The highest recorded
IOP in the more severely affected eye was between 23 and
69  mmHg  and  the  VCDR  0.5–0.9.  Control  subjects  were
recruited from participants aged ≥60 years who visited the
clinics for senile cataract, itchy eyes or floaters. They were
confirmed to be free of glaucoma or other major eye diseases.
Their IOP was <21 mmHg, with both VCDR and visual field
within  normal  range.  As  SPARC  has  been  implicated  in
systemic conditions, subjects with known systemic diseases,
such as tumor, diabetes, etc., were not included.
Gene  screening  and  copy  number  analysis  of  SPARC:
Genomic DNA was extracted from whole blood using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. DNA concentration
was measured by a ND-1000 spectrophotometer (NanoDrop
Technologies,  Wilmington,  DE).  The  target  sequences,
including part of the promoter (−1 to −318 bp upstream of the
transcription initiation site), 5′-untranslated region (5′-UTR,
+1 to +314 bp downstream of the transcription initiation site),
the entire coding regions (c.1 to c.912), exon-intron junctions,
and part of the 3′-UTR (c.912+1 to c.912+94), were screened
in the 27 members of the Philippine pedigree, 46 Chinese
patients  and  95  Chinese  controls.  Primer  sequences  were
designed  using  Primer3  [43]  (v.0.4.0)  referring  to  the
published gene sequence of SPARC (ENSG00000113140) in
Ensembl [44] (Table 2). The target sequences were amplified
using polymerase chain reaction (PCR) and analyzed by direct
DNA sequencing using the dye-termination chemistry (Big-
Dye Terminator Cycle Sequencing Reaction Kit; ver. 3.1;
Applied  Biosystems,  Inc.  [ABI],  Foster  City,  CA)  on  an
automated  sequencer  (3130XL;  ABI),  according  to  the
manufacturer’s protocol.
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2017Copy number analysis of SPARC was performed for all
the  27  subjects  from  the  pedigree,  18  randomly  selected
Chinese JPOAG patients (10 females) and 18 controls (9
females), using the TaqMan® Copy Number Assays (Applied
Biosystems).  Three  assays  were  selected  for  this  purpose
(Table 3), with one being located in proximity to the 5′-end of
the SPARC gene, one near the 3′-end, and one within the gene.
According  to  the  manufacturer’s  instructions,  the  DNA
samples were diluted to a concentration of 5 ng/μl. Each PCR
reaction mix contained 5.0 μl of 2× TaqMan® Genotyping
Master Mix, 0.5 μl of the TaqMan Copy Number target assay,
0.5 μl of the TaqMan Copy Number reference assay (RNase
P), which is known to exist only in two copies in a diploid
genome, 2.0 μl of Nuclease-free water, and 2.0 μl of DNA.
The reactions were processed in an ABI 7900HT Fast real time
PCR System using a 384-well reaction plate, with each DNA
sample analyzed in duplicates and on 95 °C/10 min for 1 cycle
followed by 92 °C/ 15 s and 60 °C/1 min for 40 cycles. Data
was collected by the SDS software (version 2.3; ABI) using
the  standard  absolute  quantification  method.  After  the
reaction,  raw  data  was  analyzed  using  a  manual  cycle
threshold (CT) of 0.2 with the automatic baseline on, and then
imported to the CopyCallerTM Software (version 1.0; ABI) for
post-PCR data analysis. In the software, copy numbers were
estimated  using  a  maximum  likelihood  algorithm.  The
analytical setting was the same for the three assays.
Data  analysis:  Segregation  analysis  was  conducted  for
variants  detected  in  the  pedigree,  including  copy  number
variation.  A  variant  is  considered  disease-causing  if  it
segregates with disease in the pedigree. For the two novel
intronic variants detected in the Chinese subjects, a web-based
program Automated Splice Site Analyses (ASSA) [45,46] was
used  to  predict  their  impacts  to  alternative  splicing.  For
variants  with  a  minor  allele  frequency  of  >1%,  Hardy–
Weinberg  Equilibrium  was  tested  by  the  χ2  test.  Variant
frequencies between patients and controls were compared by
Chi-square test or Fisher’s exact test using SPSS (ver. 16.0;
SPSS  Inc.,  Chicago,  IL).  Linkage  disequilibrium  (LD)
between  SNPs  and  haplotype  frequencies  were  estimated
using the E-M algorithm in Haploview [47] and tested for
association  using  χ2  analysis.  A  p<0.05  was  considered
statistically significant. Since no significant association was
detected, correction for multiple testing was not considered.
TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF CHINESE JPOAG AND CONTROL SUBJECTS.
     
Age at diagnosis (years) IOP (mmHg)* VCDR*
Group Sample size Female (%) Range Mean
(SD)
Range Median Range Median
JPOAG 46 19 (41.3) 6–40 24.8 (8.5) 23–69 30 0.5–0.9 0.8
Control 95 40 (42.1) 61–94 75.1 (7.1) 10–21 15 0.2–0.5 0.3
        The asterisk indicates that the IOP value is the recorded highest IOP, and the vertical cup/disc ratio (VCDR) is the measure at
        the latest follow-up visit before study enrollment.
TABLE 2. PRIMER SEQUENCES AND PCR CONDITIONS FOR SPARC SEQUENCING.
  Primer sequence      
Amplifying target Forward primer (5′→3′) Reverse primer (5′→3′) MgCl2
(mM)
Ta
(°C)
Size
(bp)
SPARC-1 (promoter
+ exon 1)
CCAGTTCCAAATCATCAAGGA GGGGTTGGTGCAACTATAGAA 1.5 59 668
SPARC-2 (exon 2) AAATGGAACCAACCTCCTCA CAATGGTCCTCATCCCAGTT 1.5 60 388
SPARC-3 (exon 3) AGCTCCCCTAGCCTGTATCC CCCTAATTTCTCAGGGCACA 1.5 60 225
SPARC-4 (exon 4) CTTTCCCTAACACCCCTGGT TCATGTAGGCTGTCCTCGTG 1.5 60 367
SPARC-5 (exon 5) TGTGCTAGTCCAGGTGATGC TGTATTCCGAAGTGCCCAAT 1.5 60 222
SPARC-6 (exon 6) CAGTGTCCCCATCTCTGAAA CCCAAGACAGGAGTCTGGAA 1.5 60 250
SPARC-7 (exon 7) AAGAAACTGTGGCCTGGAGA CTGGTGCTCAGGGGTAAATG 1.5 60 396
SPARC-8 (exon 8) CTGGCTAGTCTCTGCCTGCT TCACTCTAGGGTCTGGGGTCT 2.0 60 279
SPARC-9 (exon 9) GGGTGTGGAGCTTTTCCAT CCCCTTGCTTCTTTGTTCAG 1.5 60 229
SPARC-10 (exon 10) TCCACTGACTCCTTGGGAAG GGCAGAACAACAAACCATCC 1.5 60 198
The promoter (−1 to −318  bp from  the transcription initiation site),  5′-untranslated  region  (the noncoding  exon  1), coding  regions,
exon-intron   boundaries,   and a portion  of the 3′-untranslated   region (+1 to +94 bp downstream  the stop codon)  were  covered  by
the amplimers. In the table, Ta indicates annealing temperature and Bp indicates base pairs.
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Sequence  variants  detected  in  SPARC:  In  the  Philippine
pedigree, only one SPARC variant, namely c.912+29 C>G
(rs1053411),  was  detected  in  an  unaffected  subject.  No
sequence change was found in other family members. In the
Chinese study subjects, 11 variants were detected (Table 4),
among  which  two  were  novel,  i.e.,  IVS2+8G>T  and
IVS2+32C>T  (Figure  1).  The  heterozygous  variant
IVS2+8G>T was detected in two (2.1%) control subjects but
not in patients, while the IVS2+32C>T was detected in one
(2.2%)  patient  and  absent  in  controls.  According  to  the
ASSA program, the two novel variants were predicted to
cause no change in the information content of the donor site,
suggesting that they are not likely to be functional mutations.
The  other  9  variants  were  known  polymorphisms  in  the
dbSNP database. Except for a synonymous SNP rs2304052
(p.Glu22Glu) detected in exon 2, all other SNPs were located
in noncoding regions. All of these SNPs followed HWE in
both the control and patient groups. Moreover, the allele or
genotype  distribution  of  each  SNP  was  not  significantly
different  between  patients  and  controls,  indicating  no
association with glaucoma. Linkage disequilibrium analysis
revealed an extension of LD throughout the gene. The five
most common SNPs, rs2116780 (Intron 3), rs1978707 (Intron
4),  rs7719521  (Intron  5),  rs729853  (Intron  7),  and
rs1053411 (3′-untranslated region, 3′-UTR), were contained
in a LD block spanning approximately 11 kb (Figure 2A).
Haplotype-based  association  analysis  showed  that  no
haplotype  was  significantly  associated  with  the  disorder
(Figure 2B).
Copy  number  analysis  of  SPARC:  The  three  assays  were
unequivocally genotyped in all subjects (n=63), with call rates
of  100%,  to  obtain  predicted  copy  numbers  of  the  target
sequences  in  SPARC  in  each  subject  (Figure  3).  The
confidence of prediction was greater than 95% for each assay
in  each  subject,  except  for  the  sample  G1070,  with  a
confidence <50% for assay Hs06124887_cn. This sample was
predicted to have 3 copies of the target sequence by this assay
but was predicted to have 2 copies of the target sequences by
the other two assays with confidence >99%. Therefore, this
subject is more likely to have 2 gene copies. All the other
samples were predicted to have 2 copies of the gene by any
assay, suggesting no correlation between the copy number of
SPARC and JPOAG.
DISCUSSION
JPOAG is a subset of POAG characterized by an early age of
onset and severe elevations of intraocular pressure. It is often
inherited in an autosomal dominant pattern [20], but sporadic
cases exist. Thick, compact tissue and extracellular deposits
have been found in trabecular meshwork specimens obtained
from JPOAG patients during trabeculectomy [48]. It is thus
TABLE 3. TAQMAN® COPY NUMBER ASSAYS USED FOR COPY NUMBER ANALYSIS OF SPARC.
Assay ID Reporter dye Context sequence
Location on NCBI
assembly
Hs02667978_cn FAM GTCTCAAAACCCCAGCTCAAAATAC 151021358
Hs06106867_cn FAM GTCAGAAGGTTGTTGTCCTCATCCC 151027253
Hs06124887_cn FAM CTTCCCAGAGGTGTGGATTAATGGT 151046100
        The three assays selected are for target sequences located in proximity to the 5′- and 3′-ends of and within the gene. Any assay(s)
        detected to have gain or loss of copy number(s) may indicate, at least partially, the copy number of the SPARC gene.
TABLE 4. SPARC VARIANTS DETECTED IN CHINESE JPOAG AND CONTROL SUBJECTS.
        Minor allele frequency (%) Genotype counts
Location Sequence change Residue
change
SNP ID Case (n=92) Control
(n=190)
p Case (n=46) Control
(n=95)
p
Exon 1 c.-186G>A* – rs4958281 5 (5.4) 6 (3.2) 0.35 0/5/41 0/6/89 0.34
Intron 2 IVS2+56G>C – rs7714314 3 (3.3) 7 (3.7) 1.0 0/3/43 1/5/89 0.75
Exon 3 c.66A>G Glu22Glu rs2304052 2 (2.2) 5 (2.6) 1.0 0/2/44 0/5/90 1.0
Intron 3 IVS3+8G>T – novel 0 (0) 2 (1.1) - 0/0/46 0/2/93 -
Intron 3 IVS3+32C>T – novel 1 (1.1) 0 (0) - 0/1/45 0/0/95 -
Intron 3 IVS3+36T>G – rs2116780 36 (39.1) 77 (40.5) 0.82 7/22/17 15/47/33 0.97
Intron 3 IVS3+42T>C – rs2304051 4 (4.3) 6 (3.2) 0.73 0/4/42 0/6/89 0.73
Intron 4 IVS4+31C>T – rs1978707 45 (48.9) 92 (48.4) 0.94 10/25/11 24/44/27 0.67
Intron 5 IVS5–59T>G – rs7719521 44 (47.8) 89 (46.8) 0.88 10/24/12 22/45/28 0.86
Intron 7 IVS7+100G>A – rs729853 38 (41.3) 80 (42.1) 0.90 7/24/15 16/48/31 0.97
3′-UTR c.912+29C>G – rs1053411 39 (42.4) 80 (42.1) 0.96 8/23/15 16/48/31 0.99
        *This SNP is located 186 bp upstream the start codon “ATG”; 3′-UTR: 3′-untranslated region.
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2019likely that the abnormal trabecular meshwork and aqueous
outflow could result in an elevation of IOP and subsequently
the glaucomatous changes. The identification of the myocilin
gene  accounting  mainly  for  JPOAG  [25]  and  its  mutant
products  leading  to  elevated  IOP  [2]  also  supports  the
possibility  that  other  genes  affecting  the  structure  of
trabecular meshwork and outflow resistance may function to
regulate IOP and, once mutated, increase the risk of glaucoma.
However,  identification  of  such  genes  has  since  been
unfruitful. The tendency for familial inheritance in JPOAG
has facilitated the mapping of linkage loci for this phenotype,
and at least five loci have been identified, including GLC1A
(1q21–31,  MYOC)  [8,25],  GLC1J  (9q22)  [16],  GLC1K
(20p12) [16], GLC1M (5q22.1–32) [20], and GLC1N (15q22–
24) [21]. Thus, except for GLC1A, investigating genes on the
other loci may lead to the discovery of new disease genes for
JPOAG.
We  have  previously  mapped  the  GLC1M  locus  in  a
Philippine pedigree with JPOAG, in which affected family
members  had  moderate  IOP  elevation  (mean±SD:
32±6.3 mmHg) [20]. Therefore, it is likely that this locus
harbors  a  gene  involved  in  IOP  regulation.  We  selected
SPARC as a candidate causative gene for glaucoma mainly
based on that the SPARC protein may function to promote
extracellular matrix deposition [31] and is rich in eye tissues,
especially in the trabecular meshwork and the juxtacanalicular
region [35], that SPARC in TM cells is regulated by elevated
IOP and mechanical stretching [38,39], that SPARC null mice
have lower IOP [41], and that SPARC has been mapped to
5q31.3-q32 within the GLC1M (5q22.1–32) locus. However,
we did not find any putative mutation or copy number variants
in the affected and unaffected subjects from the GLC1M-
linked Philippine pedigree. Although some members, e.g., the
3-year-old unaffected subject, may develop glaucoma later in
life,  it  is  likely  to  be  independent  of  SPARC.  As  such,
SPARC could be excluded as the gene responsible for the
linkage signal. Discrepancy is known to exist between genetic
and physical maps. According to the Ensembl database [44],
SPARC  (ENSG00000113140)  is  physically  located  in  the
region  of  151,040,657–151,066,726  bp  at  chromosome  5.
This  region  is  outside  the  critical  interval  defined  by  the
makers D5S2051 (111,009,257–111,009,520) and D5S2090
(147,230,043–147,230,236)  [20].  Therefore,  although
SPARC by itself is a good candidate gene for glaucoma, it may
not be responsible for JPOAG in the pedigree. As such, the
causal gene for glaucoma at the GLC1M locus remains to be
identified. Recently, with the advent of the next-generation
sequencing platform [49], the sequencing capacity has been
greatly enhanced. It has been used successfully in pinpointing
the  genes  for  some  Mendelian  disorders  [50,51].  Such
technologies should speed up the identification of glaucoma
genes.
We did not detect any missense changes in SPARC in a
group of unrelated JPOAG patients and controls. Moreover,
of  the  11  variants  detected,  none  was  associated  with
glaucoma, either individually or involved in a haplotype. Our
sample of 46 patients might be small to provide adequate
statistical  power  to  detect  the  significance.  However,  the
distributions  of  the  genotypes  were  drastically  similar
between the patients and controls. It is unlikely that the lack
of association was due to insufficient power. Therefore, we
expect  that  SPARC  gene  variants  do  not  have  a  major
contribution to JPOAG genetics. However, it is still possible
that rare variants in this gene may contribute to a small portion
Figure 1. Chromatograms of the novel
SPARC variants detected in this study.
A: The variant IVS3+8G>T detected in
a control subject, this participant is also
heterozygous  for  the  rs2116780:T>G
polymorphism.  B:  The  variant
IVS3+32C>T  detected  in  a  Chinese
patient with JPOAG.
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2020of patients, which awaits confirmation by screening the gene
in a very large sample. It is also possible that variants located
outside the coding region of the gene, e.g., those at the 3′-UTR,
may contribute to the disease. It has been reported that a SNP
at the 3′-UTR of SPARC, i.e., +998C>G (equivalent to SNP
rs1053411 in the present study), was associated with systemic
sclerosis in different populations, and the C/C genotype was
correlated with a longer mRNA half-life in normal fibroblasts,
than were heterozygotes (G/C). And it was suggested that this
may contribute, at least in part, to increased SPARC gene
expression  [52].  However,  such  association  could  not  be
reproduced in another cohort of Caucasian patients [53]. In
our  study,  no  significant  association  was  detected  for
rs1053411, which is in strong LD with the other common
SNPs  detected.  According  to  the  international  HapMap
project, the SNPs that located at the 3′-UTR of SPARC are
Figure  2.  Linkage  disequilibrium  and
haplotype association analyses for the
SPARC variants detected in this study.
A:  Linkage  disequilibrium  plot  of  11
SNPs  of  the  SPARC  gene  in  the
combined  subjects.  D'  values
corresponding  to  each  SNP  pair  are
expressed as a percentage and shown
within the respective square. The five
most  common  SNPs  constitute  a
haplotype block spanning from intron 3
to the 3′-UTR of the gene. B: Haplotype-
based association analysis of the 5 most
common  SNPs  in  the  LD  block  with
JPOAG.  The  frequencies  of  each
haplotype  in  the  patient  and  control
groups  were  presented  in  percentage.
Only those haplotypes with frequencies
>1% were shown.
Figure 3. Copy number of the SPARC gene in the family members from the Philippine pedigree and the randomly selected Chinese JPOAG
patients and controls. Each bar represents the copy number prediction of the target sequence in each subject. And each color presents each
copy number assay. Thus, each individual is represented by three bars. The red arrow indicates the reference line for two copies. One sample
(G1070) was predicted to have a copy number of 3 but with a confidence of <50%.
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2021also in strong LD (data not shown). Therefore, other common
SNPs  at  the  3′-UTR  are  not  likely  to  be  associated  with
JPOAG, because the haplotypes detected in this study did not
have  disease  association  (Figure  2B).  As  such,  if  the
correlation  between  C/C  genotype  at  rs1053411  and  an
increased-SPARC expression is real, as that suggested by
Zhou et al. [52], it is likely that such an extent of increased-
SPARC expression is not causative for glaucoma. However,
whether a more severely elevated expression of the protein, if
triggered by other pathological factors, can cause glaucoma
remains to be further investigated.
So far, the involvement of the SPARC protein level in the
pathogenesis of glaucoma is unknown. SPARC occurs widely
in  extracellular  matrices  and  is  predominantly  expressed
during  embryogenesis  and  in  adult  tissues  undergoing
remodeling or repair. It is believed to play a modulatory role
in cell-cell and cell-matrix interactions, differentiation, ECM
production  and  organization,  wound  healing,  and
angiogenesis  [54-56],  suggesting  a  fundamental  role  of
SPARC to living cells [56]. SPARC has been implicated in
multiple systemic as well as ocular conditions. For example,
it is expressed at high levels in bone tissues and acts as a major
non-collagenous protein of the bone matrix [32,57]. SPARC
null  mice  have  low-turnover  osteopenia  [58],  and  it  was
suggested that SPARC may strengthen bone [59]. Moreover,
SPARC  3′-UTR  polymorphisms  had  been  associated  with
bone density in Caucasian men with idiopathic osteoporosis
[60]. Likewise, SPARC null mice have lower IOP [41]. It
could thus be hypothesized that increased-SPARC level may
elevate IOP and predispose to glaucoma. In the eye, increased
SPARC level has been correlated with cataract [61], corneal
wound  repair  [62],  and  proliferative  diabetic  retinopathy
[63].  In  glaucoma,  elevated  SPARC  expression  has  been
detected  in  the  iris  of  POAG  and  primary  angle  closure
glaucoma patients [40]. All these findings, in addition to the
genetic findings of this present study, suggest that certain
SPARC expression level could play a role in eye diseases.
However, the correlation between the expression of SPARC
and  the  occurrence  of  these  eye  diseases  remained  to  be
clarified. Recently, it has been found that SPARC deficiency
in mice resulted in improved surgical survival in a mouse
model  of  glaucoma  filtration  surgery  [64].  Whether  the
SPARC levels in glaucoma patients is correlated with the
success  rate  of  filtration  surgery  is  unknown.  If  such
correlation exists, a pre-operative detection of the SPARC
level may help with a better treatment plan.
This  study  is  one  of  several  attempts  to  evaluate  the
involvement of copy number variation in POAG. Abu-Amero
et  al.  [65]  screened  27  Caucasian  and  African-American
POAG  patients  and  12  ethnically  matched  controls  for
chromosomal copy number alterations using high resolution
array comparative genomic hybridization. No chromosomal
deletions or duplications were detected in POAG patients
compared  to  controls  [65].  Davis  et  al.  [66]  performed  a
whole-genome copy number screening in a cohort of 400
patients with POAG and 100 controls and found that rare copy
number variations in the DMXL1, TULP3, and PAK7 genes
may  affect  development  of  POAG.  Interestingly,  the
DMXL1 gene at 5q23.1 is located within the GLC1M locus.
This suggests that copy number of certain genes at this locus,
including DMXL1, may contribute to the genetics of POAG.
However, our findings in that all of the 27 subjects from the
Philippine family and the 36 Chinese subjects were detected
to carry two copies of the SPARC gene, indicate that copy
number  variation  of  SPARC  is  at  least  not  a  common
phenomenon in the two populations and thus unlikely to be a
major genetic contributor to JPOAG. Whether copy number
variations  in  other  genes  at  the  GLC1M  locus,  such  as
DMXL1, contribute to glaucoma remain to be investigated.
In summary, by mutation screening and copy number
analysis, we have excluded SPARC as the causal gene at the
GLC1M locus in the Philippine pedigree with JPOAG. Our
results also suggest that SPARC is unlikely to be a major
disease  causative  or  associated  gene  of  JPOAG.  Further
investigations are warranted to unravel the involvement of
SPARC in the pathogenesis of glaucoma, and also to identify
the causal gene at GLC1M for JPOAG.
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